Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 5,042 shares of Sight Sciences stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $2.31, for a total value of $11,647.02. Following the completion of the sale, the insider now owns 830,551 shares in the company, valued at approximately $1,918,572.81. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Sight Sciences Trading Down 0.9 %
Shares of SGHT stock opened at $2.23 on Friday. Sight Sciences, Inc. has a fifty-two week low of $2.04 and a fifty-two week high of $8.45. The company has a 50 day moving average price of $2.68 and a 200 day moving average price of $3.89. The stock has a market capitalization of $114.47 million, a P/E ratio of -2.19 and a beta of 2.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The business had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same quarter last year, the firm earned ($0.22) EPS. Equities research analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.
Hedge Funds Weigh In On Sight Sciences
A number of institutional investors and hedge funds have recently made changes to their positions in SGHT. ProShare Advisors LLC acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $36,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Sight Sciences in the 4th quarter valued at $40,000. Arkadios Wealth Advisors purchased a new stake in shares of Sight Sciences during the 4th quarter worth $47,000. WealthTrust Asset Management LLC acquired a new position in shares of Sight Sciences during the fourth quarter worth $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Sight Sciences in the fourth quarter valued at $50,000. 55.51% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. Lake Street Capital lowered their target price on Sight Sciences from $3.00 to $2.50 and set a "hold" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reissued a "hold" rating on shares of Sight Sciences in a research note on Thursday, March 6th. Piper Sandler reduced their price target on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Stifel Nicolaus lowered their price target on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Finally, UBS Group cut their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a research report on Monday, January 27th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Sight Sciences has an average rating of "Hold" and a consensus target price of $3.83.
Get Our Latest Stock Report on SGHT
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
